Mosapride
Product Sizes
10 mg
£ POA
HY-B0189-10MG
25 mg
£ POA
HY-B0189-25MG
100 mg
£ POA
HY-B0189-100MG
5 mg
£ POA
HY-B0189-5MG
50 mg
£ POA
HY-B0189-50MG
10mM/1mL
£ POA
HY-B0189-10MM
About this Product
- SKU:
- HY-B0189
- Additional Names:
- TAK-370; AS-4370
- CAS Number:
- 112885-41-3
- Extra Details:
- Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3; and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases[1][2][3][4][5][6][7].
- Molecular Weight:
- 421.89
- Purity:
- 99.87
- References:
- [1]Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.|[2]Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91.|[3]Kim HS, et al. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008 Feb;20(2):169-76.|[4]Kim YH, et al. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul). 2015 Sep;23(5):486-92.|[5]Uchida M, et al. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci. 2013;121(4):282-7.|[6]Fujisawa M, et al. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol. 2010 Feb;45(2):179-86.|[7]Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386(10):905-16.
- Research Area:
- Neurological Disease; Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- GPCR/G Protein;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling
